GO:0061515 myeloid cell development: Genes and Methods

Myeloid cell development (GO:0061515) is the biological process whose specific outcome is the progression of a myeloid cell over time, from its formation to the mature structure. Myeloid cells constitute a major branch of the hematopoietic system and include granulocytes, monocytes, macrophages, dendritic cells, mast cells, and microglia. The term encompasses the differentiation steps that generate these mature cell types from progenitor cells. Understanding this process is fundamental to immunology, hematology, and cancer biology because myeloid cells are key effectors of innate immunity and inflammation. Recent single-cell transcriptomic studies have uncovered substantial developmental heterogeneity among microglia and brain myeloid cells, indicating that myeloid development is not a single uniform trajectory but a collection of lineage-restricted programs. This heterogeneity has direct implications for how myeloid cells respond to pathogens, vaccines, and tumors. For example, myeloid cell-mediated trained innate immunity is being explored in mucosal AIDS vaccine development, where epigenetic reprogramming of myeloid progenitors shapes subsequent immune responses. Conversely, trained immunity can cause myeloid cell hypercoagulability, linking developmental and functional states of myeloid cells to thrombotic risk. The transcription factor IRF8 is a master regulator of myeloid cell development, and its dosage and timing control lineage choice between monocytes, dendritic cells, and granulocytes. In cancer, myeloid cells are often reprogrammed to suppress anti-tumor immunity, and therapeutic targeting of tumor myeloid cells is an active area of drug development. Integrated single-cell and bulk RNA sequencing has identified myeloid cell-related regulons that predict neoadjuvant immunotherapy response across cancers, underscoring the clinical relevance of myeloid developmental states. Thus, GO:0061515 provides a conceptual framework for studying how myeloid cells are generated, how their development is regulated, and how developmental defects contribute to disease.

According to the Gene Ontology, GO:0061515 (myeloid cell development) is the process whose specific outcome is the progression of a myeloid cell over time, from its formation to the mature structure. In practical terms, this includes the commitment of hematopoietic progenitors to the myeloid lineage, their proliferation and differentiation through intermediate stages, and the acquisition of mature myeloid cell morphology and function. The term is a biological process and has no synonyms in QuickGO.

Myeloid cell development is important because myeloid cells are the first responders of the innate immune system and shape the outcome of infection, vaccination, and cancer immunotherapy. Defects or reprogramming of myeloid development can lead to immune suppression in tumors, chronic inflammation, and thrombotic complications. Understanding the developmental trajectories of myeloid cells also informs the design of vaccines that harness trained innate immunity and helps predict which patients will respond to immune checkpoint blockade.

The following genes and proteins are experimentally implicated in myeloid cell development and its regulation, based on the verified literature.

Myeloid cell development is regulated by a network of transcription factors, epigenetic modifiers, and environmental signals. IRF8 is a central regulator whose expression level and post-translational modifications control lineage choice between monocytes/dendritic cells and granulocytes. Epigenetic reprogramming, including changes in histone methylation and DNA methylation, underlies trained innate immunity in myeloid cells and can be modulated by TET2 and KDM6A. In the tumor microenvironment, myeloid cell development and function are reprogrammed by cancer-derived factors, leading to immunosuppressive phenotypes that can be targeted therapeutically. Integrated single-cell and bulk RNA sequencing has identified myeloid cell-related regulons that predict immunotherapy response, highlighting the regulatory networks that govern myeloid developmental states.

Dysregulated myeloid cell development contributes to tumor progression by generating immunosuppressive myeloid populations that inhibit T cell responses. Therapeutic targeting of tumor myeloid cells aims to reprogram these cells toward an anti-tumor phenotype. Myeloid cell-targeted therapies for solid tumors are being developed, including inhibitors of signaling pathways that drive myeloid development. Integrated analysis of single-cell and bulk RNA sequencing data has revealed myeloid cell-related regulons that predict neoadjuvant immunotherapy response across cancers, suggesting that developmental states can serve as biomarkers.

Trained innate immunity in myeloid cells is being explored for mucosal AIDS vaccine development, where epigenetic reprogramming of myeloid progenitors enhances subsequent immune responses. However, trained immunity can also cause myeloid cell hypercoagulability, linking myeloid developmental states to thrombotic complications. These findings indicate that manipulating myeloid cell development has both therapeutic potential and potential risks.

Microglia and brain myeloid cells are developmentally heterogeneous, and their distinct origins and transcriptional programs have been revealed by deep single-cell RNA sequencing. This heterogeneity is relevant to neurodegenerative diseases where microglial dysfunction contributes to pathology. Understanding the developmental trajectories of brain myeloid cells may inform strategies to modulate neuroinflammation.

Myeloid cell reprogramming is involved in the pathogenesis of various diseases, including chronic inflammatory conditions and cancer. The molecular pathways that control myeloid cell development are being dissected to identify targets for therapeutic intervention. Editorial commentary has highlighted the importance of understanding these pathways for disease development.

Single-cell RNA sequencing has been used to reveal developmental heterogeneity among microglia and brain myeloid cells, identifying distinct subpopulations and trajectories. This method is essential for dissecting the transcriptional programs that drive myeloid cell development.

Integrated analysis of single-cell and bulk RNA sequencing data has identified myeloid cell-related regulons that predict neoadjuvant immunotherapy response across cancers. This approach combines the resolution of single-cell data with the statistical power of bulk data.

Epigenetic profiling, including histone modification and DNA methylation analysis, is used to study trained immunity in myeloid cells. These methods reveal how developmental and environmental cues are stably imprinted on the myeloid cell genome.

CRISPR-edited myeloid cells can be subjected to functional assays such as phagocytosis, cytokine production, and coagulation assays to link genotype to phenotype. These assays are critical for validating findings from transcriptomic and epigenetic studies.

Researchers studying myeloid cell development-related genes often need to determine whether a candidate gene is causally involved in lineage commitment, differentiation, or maturation. CRISPR-based models provide a direct way to test causality by introducing precise genetic alterations in hematopoietic progenitors or myeloid cell lines.

GO:0061515 (myeloid cell development) is a fundamental biological process that governs the generation of diverse myeloid cell populations from hematopoietic progenitors. Its regulation by transcription factors such as IRF8 and epigenetic modifiers like TET2 has profound implications for immunity, vaccine design, and cancer therapy. Dysregulation of myeloid cell development contributes to tumor progression, immunotherapy resistance, and thrombotic complications, making it a critical area of research. CRISPR-based models and advanced sequencing technologies are accelerating the discovery of new regulators and therapeutic targets in this field.